ASSAY FOR PREDICTING THE ANGIOGRAPHIC RESPONSE TO LIPID-LOWERING THERAPY IN PATIENTS

摘要

The present invention relates to an assay for testing the genetic predisposition to respond to lipid-lowering therapy in patients with coronary artery disease (CAD), comprising identifying the presence or absence of a TaqIB restriction site in intron 1 in both alleles of the cholesteryl ester transfer protein (CETP) gene by suitable molecular biological techniques; and correlating the presence of the restriction site on one or both alleles with a high or intermediate, susceptibility for lipid-lowering therapy. The invention further relates to a testkit for performing the assay and to a cholesterol ester transfer protein (CETP) gene marker for identifying individuals that may or may not be susceptible for lipid-lowering therapies.